Protalix Biotherapeutics, Inc. balance sheet

At the end of fiscal 2025, Protalix Biotherapeutics, Inc. had total assets of $82.3m, total liabilities of $34.1m and shareholders' equity of $48.2m. It held $14.7m in cash against $0 of debt: net cash of $14.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Protalix Biotherapeutics, Inc.: balance sheet, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	81	36	27	52	86	55	76	63	51	38	18	18	39	17	24	20	15	27
Receivables	—	7	1	1	2	2	0	1	2	5	5	2	3	5	5	3	9	17
Inventory	—	1	0	4	8	3	6	5	8	9	8	13	18	17	19	21	26	32
Total current assets	—	46	32	61	98	66	86	72	63	53	32	56	62	45	70	60	67	92
Total assets	—	65	52	79	113	78	97	82	72	61	45	68	74	56	84	73	82	110
Accounts payable	—	—	—	—	—	7	6	7	9	10	12	14	16	12	20	—	—	—
Deferred revenue (current)	—	5	6	9	9	1	1	1	—	10	16	5	9	13	0	—	—	—
Total current liabilities	—	19	19	26	27	64	11	66	23	25	40	86	33	32	46	26	27	31
Long-term debt	—	—	7	5	2	1	—	—	—	—	—	—	—	—	—	—	—	—
Total debt	0	0	7	5	67	67	68	73	52	48	55	—	28	28	40	0	0	0
Total liabilities	—	76	78	82	140	134	86	92	102	114	116	95	80	66	51	30	34	39
Shareholders' equity	16	−11	−26	−3	−27	−56	11	−10	−29	−53	−70	−27	−6	−11	34	43	48	71
Net debt (negative = net cash)	−81	−36	−20	−47	−19	13	−9	10	1	10	37	−18	−11	11	17	−20	−15	−27
Shares outstanding	—	—	—	—	—	—	—	—	—	30m	30m	35m	46m	54m	73m	76m	80m	—

US$ millions unless shown otherwise. Fiscal quarters.

Protalix Biotherapeutics, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	2	3	5	9	14	9	3	17
Inventory	17	21	20	21	21	26	30	32
Total current assets	48	60	61	65	67	67	86	92
Total assets	62	73	74	78	82	82	102	110
Accounts payable	20	—	—	—	—	—	—	—
Total current liabilities	24	26	24	24	22	27	27	31
Total liabilities	29	30	29	29	29	34	35	39
Shareholders' equity	32	43	45	50	53	48	67	71
Shares outstanding	—	76m	—	—	—	80m	—	—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AAPG vs PLX ADCT vs PLX BCYC vs PLX PLX vs VSTM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Protalix Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Protalix Biotherapeutics, Inc.